PDCD1 and melanoma: Given the breadth of resistance mechanisms of ICI to melanoma including the innate PD-1 Resistance Signature (IPRES) (99, 100), T cell exclusion programs such as beta catenin (101), low tumor mutational burden (102), alternative immune checkpoint expression (103) amongst a host of others indicates the means of immune escape are also likely to be heterogenous.